🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Austria / NCT07641192
Starting soon Not applicable

Theranovis Dental Gel in Patients With Gingivitis

NCT07641192 · tracked via the Priya Life Science Austria tracker
Phase
Not applicable
Started
2026-06
Last updated
2026-06-11

Condition(s) studied

GingivitisOral Health Care

Investigational drug(s) / intervention(s)

theranovis dental gel groupPlacebo group

theranovis dental gel group: The dental gel should be applied with a manual toothbrush every morning and evening after toothbrushing, left in place for 30 seconds without swallowing, and then spat out without rinsing with water afterward.

Placebo group: The dental gel should be applied with a manual toothbrush every morning and evening after toothbrushing, left in place for 30 seconds without swallowing, and then spat out without rinsing with water afterward.

Study summary

The aim of this randomized, blinded, controlled study is to compare the theranovis dental gel with a placebo product in order to determine whether an improvement in oral health can be achieved in patients with gingivitis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male and female participants aged over 18 years * At least 12 teeth per jaw (natural teeth, including restorations such as crowns and implants) * Smokers (less than 10 cigarettes per day) * Gingivitis with intact periodontium (probing depth ≤ 3.0 mm, bleeding on probing \> 10%) * Gingivitis with intact periodontium (probing depth ≤ 4 mm, no bleeding on probing at these sites) * Periodontal screening index (PSI) up to grade 2 Exclusion Criteria: * Male and female participants under 18 years of age * Fewer than 12 teeth per jaw * Individuals not capable of giving informed consent * Individuals with hypersensitivity or allergies to any of the study product ingredients * Patients with periodontitis * Patients with non-plaque-induced gingivitis * Periodontal screening index (PSI) grade 3 or higher * Current antibiotic prophylaxis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Universitätsklinik für Zahnmedizin und Mundgesundheit Graz Styria

More Medical University of Graz trials in Austria

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07641192 on ClinicalTrials.gov ↗ ← All trials in Austria